The antitumor antibiotics ravidomycin and desacetylravidomycin were studied by the biochemical A prophage induction assay. In this assay, induction of the enzyme j8-galactosidase is measured as a specific indication of the ability of an agent to directly or indirectly damage DNA. Induction was observed only when these two antibiotics were irradiated with light in the presence of the indicator organism. Drug treated with light followed by incubation with the indicator organism in the dark did not cause induction. Light in both the near UV and visible wave length ranges activated these antibiotics; near UV and visible blue wavelengths were most effective, while 597-nm light was totally ineffective. The amount of induction caused by these drugs varied directly with the dosage of light provided. Bacterial growth inhibition, as well as cytotoxicity for a human colon carcinoma cell line, was also dramatically enhanced by light. These data suggest that ravidomycin and desacetylravidomycin are potent photosensitizing, DNA-damaging agents.
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Ravidomycin (8, 20, 21) , desacetylravidomycin (20) , the gilvocarcins (1, 15, 25) , and the chrysomycins (24, 29) constitute a recently described class of structurally related antitumor antibiotics. These compounds ( Fig. 1 ) possess distinctive sugar moieties coupled to a chromophore common to all members of the class; vinyl, methyl, or ethyl side chains are linked to this chromophore at carbon 8. The vinyl species demonstrate the greatest antimicrobial and antitumor activities (1, 15, 16, 29) .
Results of mode of action studies have indicated that these antibiotics interfere primarily with DNA synthesis (22, 26, 27) . Examination of gilvocarcin V and chrysomycin A binding to covalently closed circular DNA in a cell-free system revealed that DNA strand interruption by these drugs was dependent on exposure to light (27) . The activity of both drugs in the biochemical X prophage induction assay (BIA) (7), which was the original detection system for the gilvocarcin complex in a natural products screening program (28) , was subsequently shown to be promoted by light (6) . In this report, we describe the effect of light on the BIA response, inhibition of bacterial growth, and cytotoxicity against cultured cells for ravidomycin and desacetylravidomycin. O-Nitrophenyl-,-D-galactopyranoside, chloramphenicol, and ampicillin were obtained from Sigma Chemical Co., St. Louis, Mo.
MATERIALS AND METHODS
BIA. The BIA was conducted by a modification of the method of Elespuru and Yarmolinsky (7) . Briefly, a culture of E. coli BR513 grown to log phase (A6w = 0.4) in LBE broth was diluted 1:10 in fresh LBE supplemented with 10 ,ug of ampicillin per ml. This cell suspension (100 ,ul) was added to 10- (Fig. 3) was determined by irradiating drug-cell mixtures with visible light at various fluence rates. As light intensity was increased, the concentrations of both drugs required to give peak enzyme induction and toxicity decreased. The reduction in actual peak enzyme activity at 100 Wm-2 compared with that at the lower fluence rates probably reflects enhanced antibiotic toxicity at this highest level of light treatment. These data suggest that the activities of ravidomycin and desacetylravidomycin in the BIA vary directly with the dosage of light that is introduced. The activity of desacetylravidomycin treated with light before analysis in the BIA was examined (Fig. 4) (Table 2 ). In a clonogenicity assay, treatment with either antibiotic did not result in a decrease in the number of surviving colonies at concentrations as high as 0.1 ,ug/ml when cultures were held in the dark. However, in the light both drugs promoted a decline in surviving colonies. Desacetylravidomycin, the more active of the two compounds, demonstrated total inhibition at 0.01 ,ug/ml and a significant reduction even at the lowest concentration tested (0.0002 ,ug/ml). 
DISCUSSION
In this study is presented a comprehensive analysis of the photoactivation properties of ravidomycin and desacetylravidomycin, results of which suggest that there is a correlation between their light-dependent initiation of DNA damage and the dramatic enhancement by light of their antimicrobial and cytotoxic activities. Photoactivation of these antibiotics in the BIA varies directly with the dosage of light and appears to be maximal at wavelengths in the visible blue and near UV (UVA) ranges. Application of light to drug prior to addition to cells did not result in induction; therefore, it appears that drug must be in contact with its cellular target for the light-dependent reaction to occur. It seems likely that these data are related to an earlier observation of photoactivated DNA damage by the antibiotics gilvocarcin V and chrysomycin A in a cell-free assay (27) and the subsequent indication of their light-initiated activities in the BIA (6) .
Other natural products likewise have been reported to affect DNA via photodynamic reactions. The plant-derived furocoumarins (23), or psoralens, and the furoquinolines (18, 19) form covalent mono-or diadducts with DNA only when UVA light is introduced. Similarly, the psoralens require UVA treatment for their activity in the BIA (data not shown [6] ). Camptothecin, a cytotoxic antitumor alkaloid, initiates single-stranded breaks in supercoiled DNA only when the drug-DNA mixture is irradiated with UVA light (14) . Lightactivated DNA damage promoted by camptothecin, which was observed in the absence of enzymes or other cellular constituents, presumably occurs by a mechanism that is distinct from its induction of protein-linked DNA breaks via mammalian DNA topoisomerase I (12) . Recently, daunomycin has been observed to initiate DNA cleavage when visible light is applied to drug-DNA mixtures (10), while bleomycin, which initiates DNA damage without light, demonstrates enhanced activity if light at 300 to 350 nm is introduced (5) . The poorly active cobalt (III) bleomycins efficiently introduce single-stranded breaks in DNA in the presence of UV or visible radiation (2) .
As was observed with other photosensitizers (13), activation of ravidomycin and desacetylravidomycin seems to be optimal at wavelengths (362 and 400 nm) close to their absorption maxima (350 and 392 nm) (8) . The same absorption peaks were retained when these drugs were tested in the presence of DNA (data not shown). It is interesting, however, that both compounds still induced in the BIA, although only at very high drug concentrations, when light at 497 nm was applied (Fig. 2) . Absorption of light within this wavelength region was not observed with these drugs in the presence of absence of DNA (data not shown), nor has it been reported for any of the antibiotics within this class. It is possible that these potent photosensitizers can even be activated by the absorption of light energy at levels that cannot be detected by conventional analytical methods.
Although our data suggest that ravidomycin and desacetylravidomycin only initiate DNA damage with light exposure, the extent to which this light reaction may contribute to their in vivo antitumor activities remains uncertain. While irradiation with light was absolutely required for induction in the BIA, a distinct toxic reaction was still observed for both drugs in the dark at concentrations exceeding 5 ptg/ml (Fig. 2) . Antimicrobial activity likewise was detected for these antibiotics and gilvocarcin V in the absence of light (Table 1) . These activities may reflect blocks in macromolecular synthesis because of intercalative drug binding to DNA, which has, been observed to occur in the dark for members of this antibiotic class (26, 27) . The failure of gilvocarcin M, which does not respond to light in the BIA (6) , to demonstrate significant antitumor activity (1, 15) has been cited as evidence that the in vivo antitumor properties of gilvocarcin V may be related to light-mediated activation (6) . H-owever, other properties of the methyl component that are unrelated to light activation, such as a reduced capacity to intercalate into DNA (11, 26) or possibly altered pharmacological behavior, may be responsible for its reduced in vivo activity. Further studies are necessary to establish conclusively whether ambient light or another endogenous activating mechanism might have contributed to any extent to the reported in vivo antitumor activity of the active antibiotic species.
The significance of the light reaction is demonstrated by the potent in vitro photosensitizing activities of ravidormycin and desacetylravidomycin. The enhanced cytotoxicity of these compounds for human colon carcinoma cells because of a brief exposure to visible light, which was at least 500-fold for ravidomycin and even greater for desacetylravidomycin (Table 2) , dramatically illustrates this point. This suggests that one could introduce light directly into a tumor in an animal treated with levels of these drugs that are well below those that would normally produce any therapeutic or generalized toxic effect and could target a favorable, toxic response solely to the tumor site. Such tumor-localized phototherapy has been practiced with hematoporphyrin derivative for a variety of cancers (3, 4) and with the psoralens in the treatment of cutaneous T-cell lymphomas (9) and the extracorpdreal therapy of leukemias (R. L. Edelson, U.K. patent application 2,100,143, December 1982). We realize that the UVA-visible blue wavelengths required for optimal activation of ravidomycin and desacetylravidomycin are more limited in tissue penetration than are longer wavelengths (17, 30) . However, the actual potential of these highly potent photosensitizers in phototherapy will only become apparent through direct in vivo experimentation.
LITERATURE CITED
